Dr. Burgess on Key Data in Metastatic Castration-Sensitive Prostate Cancer

Earle Burgess, MD
Published: Tuesday, Nov 27, 2018



Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, discusses pivotal clinical trials in metastatic castration-sensitive prostate cancer.

Researchers learned 4 years ago that the addition of docetaxel to androgen deprivation therapy (ADT) improved overall survival in patients with newly diagnosed metastatic disease; this was reported in the pivotal phase III CHAARTED trial.

Conducted in the United Kingdom, the multi-arm STAMPEDE trial evaluated the addition of abiraterone acetate (Zytiga) plus prednisone to ADT in patients with relapsed prostate cancer. This trial confirmed the findings of CHAARTED; the addition of chemotherapy to ADT improved patient outcomes, Burgess says.

The use of abiraterone acetate in combination with ADT has also been evaluated in patients with metastatic castration-sensitive prostate cancer. The randomized phase III LATITUDE trial showed that the addition of abiraterone acetate to ADT at the time of diagnosis improved overall survival in this patient population. This study led to the February 2018 FDA approval of abiraterone in combination with prednisone for high-risk patients.
SELECTED
LANGUAGE


Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, discusses pivotal clinical trials in metastatic castration-sensitive prostate cancer.

Researchers learned 4 years ago that the addition of docetaxel to androgen deprivation therapy (ADT) improved overall survival in patients with newly diagnosed metastatic disease; this was reported in the pivotal phase III CHAARTED trial.

Conducted in the United Kingdom, the multi-arm STAMPEDE trial evaluated the addition of abiraterone acetate (Zytiga) plus prednisone to ADT in patients with relapsed prostate cancer. This trial confirmed the findings of CHAARTED; the addition of chemotherapy to ADT improved patient outcomes, Burgess says.

The use of abiraterone acetate in combination with ADT has also been evaluated in patients with metastatic castration-sensitive prostate cancer. The randomized phase III LATITUDE trial showed that the addition of abiraterone acetate to ADT at the time of diagnosis improved overall survival in this patient population. This study led to the February 2018 FDA approval of abiraterone in combination with prednisone for high-risk patients.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x